, Singapore
Photo from Envato Elements

iX Biopharma widens net loss by 12% in FY2024

Loss per share stood at $0.0141.

iX Biopharma reported a net loss by 12% to $10.8m in FY2024 from $9.6m a year ago.

Revenue for the period slipped 1% to $5.95m from $5.91m in FY2023, whilst gross profit fell 55% to $1.04m from $2.32m in FY2023.

Loss per share stood at $0.0141 from $0.0126 a year ago.

Follow the link for more news on

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!